JABRYUS Trademark

Trademark Overview

On Wednesday, June 20, 2018, a trademark application was filed for JABRYUS with the United States Patent and Trademark Office. The USPTO has given the JABRYUS trademark a serial number of 88008051. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 24, 2022. This trademark is owned by Pfizer Inc.. The JABRYUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
jabryus

General Information

Serial Number88008051
Word MarkJABRYUS
Filing DateWednesday, June 20, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 24, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 23, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 26, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, January 24, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 24, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, May 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, May 22, 2021EXTENSION 5 GRANTED
Thursday, May 13, 2021EXTENSION 5 FILED
Friday, May 21, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, May 13, 2021TEAS EXTENSION RECEIVED
Tuesday, November 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 13, 2020EXTENSION 4 GRANTED
Friday, November 13, 2020EXTENSION 4 FILED
Friday, November 13, 2020TEAS EXTENSION RECEIVED
Saturday, April 25, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 23, 2020EXTENSION 3 GRANTED
Thursday, April 23, 2020EXTENSION 3 FILED
Thursday, April 23, 2020TEAS EXTENSION RECEIVED
Wednesday, April 22, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, April 22, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 22, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 22, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, April 22, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, November 23, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 21, 2019EXTENSION 2 GRANTED
Thursday, November 21, 2019EXTENSION 2 FILED
Thursday, November 21, 2019TEAS EXTENSION RECEIVED
Tuesday, November 19, 2019CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Monday, November 18, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, April 3, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 1, 2019EXTENSION 1 GRANTED
Monday, April 1, 2019EXTENSION 1 FILED
Monday, April 1, 2019TEAS EXTENSION RECEIVED
Tuesday, December 18, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 23, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 23, 2018PUBLISHED FOR OPPOSITION
Wednesday, October 3, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 19, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 19, 2018ASSIGNED TO EXAMINER
Tuesday, June 26, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, June 23, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

jabryus preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological